We believe that the 14-3-3 proteins clearly affected the phosphorylation of tau in sCJD, that the markers is pathologically increased in AD, and that 14-3-3 β may also interact with p-tau, although this remains to be determined by cellular localization studies performed with specific 14-3-3 isoforms and other binding proteins associated with neurodegenerative disorders. This evidence concerns the gene MAPT and Alzheimer disease.